top of page

Pipeline        AIM Biologicals         AEZS-150        AEZS-130 (Macimorelin)        Macimorelin Dx         

Pipeline        AIM Biologicals         AEZS-150        AEZS-130 (Macimorelin)        Macimorelin Dx         Publications        


Our Commercial and Development Pipeline is Focused on Serving the
Unmet Medical Needs of Patients Across a Range of Therapeutic Areas

Therapeutic Development Pipeline

AEZS_Blue Pipe 2.6.23.png

Diagnostic Pipeline


Commercial Rights

Aeterna is regaining rights to macimorelin (Macrilen™) in the United States and Canada in May 2023 and is engaged in robust business development efforts to identify and secure a new development and commercialization partner in these territories. 

bottom of page